Artiva Biotherapeutics, Inc.
ARTV
$10.79
-$0.09-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | 0.00 | 0.00 |
| SG&A Expenses | 20.29M | 20.27M | 20.27M | 20.28M | 19.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.15M | 92.07M | 89.81M | 86.15M | 81.58M |
| Operating Income | -96.15M | -92.07M | -89.81M | -86.15M | -81.58M |
| Income Before Tax | -90.82M | -87.07M | -83.87M | -79.19M | -75.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -90.82 | -87.07 | -83.87 | -79.19 | -75.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.82M | -87.07M | -83.87M | -79.19M | -75.13M |
| EBIT | -96.15M | -92.07M | -89.81M | -86.15M | -81.58M |
| EBITDA | -93.46M | -89.43M | -87.21M | -83.60M | -79.07M |
| EPS Basic | -3.31 | -3.55 | -3.43 | -3.25 | -3.29 |
| Normalized Basic EPS | -2.12 | -2.27 | -2.19 | -2.09 | -2.12 |
| EPS Diluted | -3.31 | -3.55 | -3.43 | -3.25 | -3.29 |
| Normalized Diluted EPS | -2.12 | -2.27 | -2.19 | -2.09 | -2.12 |
| Average Basic Shares Outstanding | 113.15M | 98.11M | 97.77M | 97.59M | 92.00M |
| Average Diluted Shares Outstanding | 113.15M | 98.11M | 97.77M | 97.59M | 92.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |